Vcare PharmaTech's Eratrectinib Revolutionizes Cancer Treatment in China
Eratrectinib, a next-generation TRK inhibitor developed by Vcare PharmaTech, has been granted marketing approval in China. The approval signifies a significant advancement in cancer treatment, particularly for patients with advanced.....
Subscribe for Full Access!
Gain valuable sourcing and trade intelligence from our database of millions of data points spanning 20+ years!
